Indications :
Non-small cell lung cancer with KRAS G12C mutation.
Product Introduction :
Sotorasib is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This article summarizes the milestones in the development of sotorasib leading to this first approval for KRAS G12C-mutated NSCLC.
Administration and Dosage :
The recommended dose is 960 mg (eight 120 mg tablets) orally once daily until disease progression or unacceptable toxicity.
